Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
The DOI matches its Crossref record; 120 of the 121 references it cites were found in a registry or an index.
Abstract
The opposing actions of histone acetyltransferases (HATs) and histone deacetylases (HDACs) allow gene expression to be exquisitely regulated through chromatin remodelling. Aberrant transcription due to altered expression or mutation of genes that encode HATs, HDACs or their binding partners, is a key event in the onset and progression of cancer. HDAC inhibitors can reactivate gene expression and inhibit the growth and survival of tumour cells. The remarkable tumour specificity of these compounds, and their potency in vitro and in vivo, underscore the potential of HDAC inhibitors as exciting new agents for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Acetylation of the core histones of nucleosomes strongly influences gene transcription (Khochbin et al., 2001; Johnstone, 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
In the citing paper
“Class I HDACs are ubiquitously expressed and are primarily located in the nucleus, while the class II enzymes can shuttle between the nucleus and cytoplasm and demonstrate tissue-specific expression (Johnstone, 2002; Marks et al., 2001; Vigushin and Coombes, 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
In the citing paper
“Two related classes of eukaryotic zinc-containing HDACs have been recognized based upon sequence similarity: class I (HDAC1, 2, 3, and 8) and class II (HDAC4, 5, 6, 7, 9, and 10) (Johnstone, 2002; Gao et al., 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756 · cited 1×
“In general terms, condensed chromatin mediates transcriptional repression, whereas transcriptionally active genes are in areas of open chromati”
BackgroundCrystal structure of the nucleosome core particle at 2.8 Å resolution
Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997) · Nature · doi:10.1038/38444 · Cited by 9,466
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510 · cited 1×
“pl?locus=sir2">Sir2 , a yeast transcriptional repressor that requires the cofactor NAD + for its deacetylase activit”
BackgroundhSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659 · cited 3×
“Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of DAXX in acute promyelocytic leukaemia with t(15;17).”
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887 · cited 1×
“asp?DrugCode=1%2D1882&DrugName=VALPROIC+ACID+ORAL&DrugType=1">valproic acid , inhibit HDAC activity and affect the expression of numerous genes with disparate cellular function”
BackgroundHistone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 1×
“gov/cancer_information/cancer_type/leukemia/">leukaemias and solid tumours to express differentiated characteristics and stop proliferatin”
BackgroundCameron, E. E., Bachman, K. E., Myöhänen, S., Herman, J. G., & Baylin, S. B. (1999) · Nature Genetics · doi:10.1038/5047 · Cited by 1,857
Acetylation of Histones and Transcription-Related Factors
Sterner, D. E., & Berger, S. L. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.2.435-459.2000 · Cited by 1,780 · cited 5×
“Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.”
BackgroundInfluential
Research works printed but not linked: 1
- Ruefli, A. A. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-gp expressing cells. Int. J. Cancer. (in the press).
Cited by
From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites
Koh, A., De Vadder, F., Kovatcheva-Datchary, P., & Bäckhed, F. (2016) · Cell · doi:10.1016/j.cell.2016.05.041 · Cited by 7,070
“, Johnstone, A.M., Lobley, G.E., Wallace, R.J., et al. (2011). High-protein, reduced-carbohydrate weight-loss diets promote metabolite profiles likely to be detrimental to colonic health.”
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
“A large number of studies have demonstrated that various TNF receptor super family members and their ligands are transcriptionally activated following HDACi treatment (see Ref”
BackgroundSelf-citationHistone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
“A relatively wide range of structures have been identified that are able to inhibit the activity of class 1, class 2 and class 4 HDAC”
BackgroundDrug discovery from medicinal plants
Balunas, M. J., & Kinghorn, A. D. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.09.012 · Cited by 1,810
“…at UIC, as well as panels of diverse mechanistic and cell-based assays at RTI and BMS. Examples of mechanism-based assays include a proteasome inhibition assay (Almond and Cohen, 2002; Adams, 2004) and a histone deacetylase (HDAC) inhibition assay (Johnstone, 2002; Villar-Garea and Esteller, 2004).”
MethodHistone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Self-citationGregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
“Consistent with this prediction, HDAC1 and HDAC2 exist in similar complexes including Sin3, NuRD/ NRD/Mi2, and CoREST.(2,32,33) They are also both widely expressed.”
BackgroundInfluentialDuvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141
“All patients 4/13 (31) 9.1, 61.4 1/11 (9) 0.2, 41.3 3/9 (33) 7.5, 70.1 8/33 (24) 11.1, 42.3 Stage less than IIB* 0/2 (0) 0.0, 84.2 0/1 (0) 0.0, 97.5 1/2 (50) 1.3, 98.7 1/5 (20) 0.5, 71.6 Stage at least IIB† 4/11 (36) 10.9, 69.2 1/10 ( 10 ) 0.3, 44.5 2/7 (29) 3.7, 71.0 7/28 (25) 10.7, 44.9 Sezary syndrome 1/3 (33) 0.8,…”
InfluentialHaggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066
The role of histone deacetylases (HDACs) in human cancer
Ropero, S., & Esteller, M. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.01.001 · Cited by 997
“…of acetylated lysine in histone tails is associated with a more relaxed chromatin state and gene-transcription activation, while the deacetylation of lysine residues is associated with a more condensed chromatin state and transcriptional gene silencing ( Johnstone, 2002; Iizuka and Smith, 2003).”
BackgroundDeacetylase inhibition promotes the generation and function of regulatory T cells
Tao, R., de Zoeten, E. F., Özkaynak, E., Chen, C., Wang, L., Porrett, P. M., Li, B., Turka, L. A., Olson, E. N., Greene, M. I., et al. (2007) · Nature Medicine · doi:10.1038/nm1652 · Cited by 924
“HATs generally increase accessibility and promote gene transcription, whereas HDACs typically dampen histone-DNA and histone–nonhistone protein interaction”
BackgroundAlao, J. P. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-24 · Cited by 871
“Histone deacetylase inhibitors (HDACIs) have shown potent selective activity as anti cancer agents both in vitro and in vivo [140-146].”
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070779 · Cited by 713
Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases
Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., et al. (2004) · Structure · doi:10.1016/j.str.2004.04.012 · Cited by 710
Zhang, R., Poustovoitov, M. V., Ye, X., Santos, H. A., Chen, W., Daganzo, S. M., Erzberger, J. P., Serebriiskii, I. G., Canutescu, A. A., Dunbrack, R. L., et al. (2005) · Developmental Cell · doi:10.1016/j.devcel.2004.10.019 · Cited by 699
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Mottamal, M., Zheng, S., Huang, T., & Wang, G. (2015) · Molecules · doi:10.3390/molecules20033898 · Cited by 680
“Although not fully understood, the clinical activities of these compounds are thought to be mediated in part by the induction of histone acetylation where the chromatin configuration adopts a permissive or more open form for potential reactivation of aberrantly suppressed genes, leading to inhibition of cell prolifera…”
BackgroundPostbiotics and Their Potential Applications in Early Life Nutrition and Beyond
Wegh, C. A. M., Geerlings, S. Y., Knol, J., Roeselers, G., & Belzer, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194673 · Cited by 639
Vannini, A., Volpari, C., Filocamo, G., Casavola, E. C., Brunetti, M., Renzoni, D., Chakravarty, P., Paolini, C., De Francesco, R., Gallinari, P., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404603101 · Cited by 638
Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells
Nebbioso, A., Clarke, N., Voltz, E., Germain, E., Ambrosino, C., Bontempo, P., Alvarez, R., Schiavone, E. M., Ferrara, F., Bresciani, F., et al. (2005) · Nature Medicine · doi:10.1038/nm1161 · Cited by 610
Epigenetics: A New Bridge between Nutrition and Health
Choi, S.-W., & Friso, S. (2010) · Advances in Nutrition · doi:10.3945/an.110.1004 · Cited by 598
“Interestingly, HDAC inhibitors have been recognized as potential cancer therapeutic agents, because they induce cell cycle arrest and apoptosis by enhancing the expression of certain proapoptotic or cell cyclemediating genes (27,28).”
BackgroundWilson, A. J., Byun, D.-S., Popova, N., Murray, L. B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L. H., & Mariadason, J. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510023200 · Cited by 575
Multi-targeted prevention of cancer by sulforaphane
Clarke, J. D., Dashwood, R. H., & Ho, E. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.04.018 · Cited by 563
“Strikingly, the effects of HDAC inhibition occur preferentially in cancer cells and not normal cells [36].”
Background(2011) · PubMed Central · Cited by 560
Gui, C.-Y., Ngo, L., Xu, W. S., Richon, V. M., & Marks, P. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307708100 · Cited by 550
Peart, M. J., Smyth, G. K., van Laar, R. K., Bowtell, D. D., Richon, V. M., Marks, P. A., Holloway, A. J., & Johnstone, R. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500369102 · Cited by 539
Self-citationHistone Deacetylase Inhibitors
Miller, T. A., Witter, D. J., & Belvedere, S. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0303094 · Cited by 530
Gene-promoter hypermethylation as a biomarker in lung cancer
Belinsky, S. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1432 · Cited by 533
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis
Zhu, P., Martin, E., Mengwasser, J., Schlag, P., Janssen, K.-P., & Göttlicher, M. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00114-x · Cited by 525
“In promyelo- nonhematopoietic origin (Johnstone, 2002; Krämer et al., 2001; cytic leukemia, a prominent cause is the expression of fusion Marks et al., 2001; Melnick and Licht, 2002; Remiszewski, 2002). proteins from chromosomal translocations that code for aber- However, compared to the fusion…”
Background(2003) · PubMed · Cited by 519
Insinga, A., Monestiroli, S., Ronzoni, S., Gelmetti, V., Marchesi, F., Viale, A., Altucci, L., Nervi, C., Minucci, S., & Pelicci, P. G. (2005) · Nature Medicine · doi:10.1038/nm1160 · Cited by 516
Resveratrol as an anticancer nutrient: molecular basis, open questions and promises
Signorelli, P., & Ghidoni, R. (2005) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2005.01.017 · Cited by 489
“Moreover, epigenetic regulation of gene transcription (DNA methylation and histone methylation, phosphorylation, acetylation and ubiquitination) is frequently associated with cancer promotion and progression [196], and the activity of deacetylases, by targeting transcriptional factors among other substrates, contribut…”
BackgroundEpigenetics in cancer: Targeting chromatin modifications
Ellis, L., Atadja, P. W., & Johnstone, R. W. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0860 · Cited by 479
“Chromatin consists of DNA, histones, and nonhistone proteins condensed into nucleoprotein complexes and it functions as the physiological template of all eukaryotic genetic information (4).”
BackgroundSelf-citationDifferentiation therapy revisited
de Thé, H. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.103 · Cited by 462
Histone deacetylase inhibitors in cancer therapy
Johnstone, R. W., & Licht, J. D. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00165-x · Cited by 449
“Both naturally occurring and synthetic HDI have been characterized (Johnstone, 2002; Kelly et al., 2002).”
BackgroundInfluentialSelf-citationHistone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse
Mishra, N., Reilly, C. M., Brown, D. R., Ruiz, P., & Gilkeson, G. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16153 · Cited by 408
“HDIs are believed to modulate gene expression either positively or negatively in a gene-specific manner (8, 32).”
Laird, P. W. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi113 · Cited by 398
“It is now realized that CpG island hypermethylation is just one facet of an integrated change in chromatin structure and in histone modifications (10,11), including histone H3 and H4 deacetylation (12), histone H3 lysine 9 methylation (13), histone H4 sumoylation (14) and reduced histone H3 lysine 4 methylation (15,16…”
BackgroundProtein post-translational modifications and regulation of pluripotency in human stem cells
Wang, Y.-C., Peterson, S. E., & Loring, J. F. (2014) · Cell Research · doi:10.1038/cr.2013.151 · Cited by 395
Tremolizzo, L., Carboni, G., Ruzicka, W. B., Mitchell, C. P., Sugaya, I., Tueting, P., Sharma, R., Grayson, D. R., Costa, E., & Guidotti, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.262658999 · Cited by 384
Pei, X.-Y., Dai, Y., & Grant, S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0561 · Cited by 382
“transcription of genes involved in various cellular processes, including differentiation, particularly in malignant hematopoietic cells (17).”
BackgroundSuppression of Class I and II Histone Deacetylases Blunts Pressure-Overload Cardiac Hypertrophy
Kong, Y., Tannous, P., Lu, G., Berenji, K., Rothermel, B. A., Olson, E. N., & Hill, J. A. (2006) · Circulation · doi:10.1161/circulationaha.106.625467 · Cited by 377
Armeanu, S., Bitzer, M., Lauer, U. M., Venturelli, S., Pathil, A., Krusch, M., Kaiser, S., Jobst, J., Smirnow, I., Wagner, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4252 · Cited by 358
“In the last few years, HDAC-I have been shown to exhibit profound antitumor effects in a broad range of tumor entities (9, 10), among them hepatocellular carcinoma models (11–13).”
InfluentialDistribution of histone deacetylases 1–11 in the rat brain
Broide, R. S., Redwine, J. M., Aftahi, N., Young, W., Bloom, F. E., & Winrow, C. J. (2007) · Journal of Molecular Neuroscience · doi:10.1007/bf02686117 · Cited by 347
Regulation of histone deacetylase activities
Sengupta, N., & Seto, E. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20179 · Cited by 346
Valproate Induces Replication-independent Active DNA Demethylation
Detich, N., Bovenzi, V., & Szyf, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303740200 · Cited by 345
Smith, B. J., Miller, R. A., Ericsson, A. C., Harrison, D. C., Strong, R., & Schmidt, T. M. (2019) · BMC Microbiology · doi:10.1186/s12866-019-1494-7 · Cited by 349
“Likewise, both butyrate and propionate activate FFAR3—which can result in increased secretion of PYY and GLP-1 [43, 44] with implications for glucose homeostasis [45]—and inhibit histone deacetylases [46], with downstream effects on both inflammation [47] and carcinogenesis [48].”
BackgroundExpression profile of class I histone deacetylases in human cancer tissues
Nakagawa, M., Oda, Y., Eguchi, T., Aishima, S.-I., Yao, T., Hosoi, F., Basaki, Y., Ono, M., Kuwano, M., Tanaka, M., et al. (2007) · Oncology Reports · doi:10.3892/or.18.4.769 · Cited by 341
Cell-cycle dysregulation and anticancer therapy
Stewart, Z. A., Westfall, M. D., & Pietenpol, J. A. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(03)00026-9 · Cited by 344
Fournel, M., Bonfils, C., Hou, Y., Yan, P. T., Trachy-Bourget, M.-C., Kalita, A., Liu, J., Lu, A.-H., Zhou, N. Z., Robert, M.-F., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2026 · Cited by 332
Huang, B. H., Laban, M., Leung, C. H.-W., Lee, L., Lee, C. K., Salto-Tellez, M., Raju, G. C., & Hooi, S. C. (2005) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401567 · Cited by 337
“three groups based on homology to yeast HDAC enzymes and dependence on NADþ for activity.(5,23,24) Despite the”
Histone deacetylase inhibitors
Monneret, C. (2005) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2004.10.001 · Cited by 338
Retinoids in cancer therapy and chemoprevention: Promise meets resistance
Freemantle, S. J., Spinella, M. J., & Dmitrovsky, E. (2003) · Oncogene · doi:10.1038/sj.onc.1206936 · Cited by 312
Myzak, M. C., Tong, P. S. L., Dashwood, W., Dashwood, R. H., & Ho, E. (2007) · PubMed · doi:10.3181/00379727-207-2320227 · Cited by 313
“HDAC changes have been linked to the progression of several cancers, including prostate cancer (1, 3, 4, 6).”
BackgroundPlumb, J. A., Finn, P. W., Williams, R. J., Bandara, M. J., Romero, M., Watkins, C. J., Thangue, N. B. L., & Brown, R. (2003) · PubMed · Cited by 369
Interplay between microRNAs and the epigenetic machinery: An intricate network
Iorio, M. V., Piovan, C., & Croce, C. M. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2010.05.005 · Cited by 306
Qian, D. Z., Kachhap, S. K., Collis, S. J., Verheul, H. M. W., Carducci, M. A., Atadja, P., & Pili, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4598 · Cited by 299
“Treatment of transformed cells with HDAC inhibitors results in growth inhibition ( 10 ).”
BackgroundAlcendor, R. R., Kirshenbaum, L. A., Imai, S.-I., Vatner, S. F., & Sadoshima, J. (2004) · Circulation Research · doi:10.1161/01.res.0000147557.75257.ff · Cited by 303
Ellis, L., Pan, Y., Smyth, G. K., George, D. J., McCormack, C., Williams-Truax, R., Mita, M., Beck, J., Burris, H., Ryan, G., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4262 · Cited by 297
Self-citationInhibition of DNA methylation and histone deacetylation prevents murine lung cancer.
Belinsky, S. A., Klinge, D. M., Stidley, C. A., Issa, J. J., Herman, J. G., March, T. H., & Baylin, S. B. (2003) · PubMed · Cited by 320
Zhao, Y., Lu, S., Wu, L., Chai, G., Wang, H., Chen, Y., Sun, J., Yu, Y., Zhou, W., Zheng, Q., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2782-2790.2006 · Cited by 277
“Histone deacetylase (HDAC) inhibitors have been extensively studied in basic biological research to gain an understanding of basic chromatin structure and transcriptional control and have recently been introduced as potential clinical treatments for cancer (36, 54, 55, 71, 74).”
BackgroundRegulation of microglial inflammatory response by sodium butyrate and short‐chain fatty acids
Huuskonen, J., Suuronen, T., Nuutinen, T., Kyrylenko, S., & Salminen, A. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705682 · Cited by 275
“Butyrate and other SCFAs are promising anticancer therapeutics (Chen et al., 2003) as well as other histone deacetylase inhibitors (Johnstone, 2002).”
BackgroundRamalingam, S. S., Maitland, M. L., Frankel, P., Argiris, A. E., Koczywas, M., Gitlitz, B., Thomas, S., Espinoza-Delgado, I., Vokes, E. E., Gandara, D. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9094 · Cited by 273
“members of a novel class of anticancer agents that act by regulating chromatin structure and function.(6)”
BackgroundLin, H., Hu, C., Chan, H., Liew, Y., Huang, H., Lepescheux, L., Bastianelli, E., Baron, R., Rawadi, G., & Clément‐Lacroix, P. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707165 · Cited by 272
“nicotinamide adenine dinucleotide (NAD)-dependent enzymes (Johnstone, 2002; Blanchard and Chipoy, 2005).”
BackgroundInfluentialDose-dependent Blockade to Cardiomyocyte Hypertrophy by Histone Deacetylase Inhibitors
Antos, C. L., McKinsey, T. A., Dreitz, M., Hollingsworth, L. M., Zhang, C.-L., Schreiber, K., Rindt, H., Gorczynski, R. J., & Olson, E. N. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303113200 · Cited by 269
Cancer Epigenetics: Modifications, Screening, and Therapy
Einav Nili, G.-Y., Saito, Y., Egger, G., & Jones, P. A. (2008) · Annual Review of Medicine · doi:10.1146/annurev.med.59.061606.095816 · Cited by 270
Qian, D. Z., Kato, Y., Shabbeer, S., Wei, Y., Verheul, H. M. W., Salumbides, B., Sanni, T., Atadja, P., & Pili, R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1132 · Cited by 268
Reddy, P., Sun, Y., Toubai, T., Duran-Struuck, R., Clouthier, S. G., Weisiger, E., Maeda, Y., Tawara, I., Krijanovski, O., Gatza, E., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34712 · Cited by 265
“HDAC inhibitors modulate the expression of multiple genes and are currently being evaluated as antitumor agents (6, 7).”
BackgroundZhang, Q., Wang, H. Y., Marzec, M., Raghunath, P. N., Nagasawa, T., & Wasik, M. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501959102 · Cited by 262
Tremolizzo, L., Doueiri, M.-S., Dong, E., Grayson, D. R., Davis, J., Pinna, G., Tueting, P., Rodriguez-Menendez, V., Costa, E., & Guidotti, A. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.046 · Cited by 258
Trichostatin A-induced histone acetylation causes decondensation of interphase chromatin
Tóth, K. F., Knoch, T. A., Wachsmuth, M., Frank-Stöhr, M., Stöhr, M., Bacher, C. P., Müller, G., & Rippe, K. (2004) · Journal of Cell Science · doi:10.1242/jcs.01293 · Cited by 260
“For image correlation spectroscopy the segmentation was carried out by setting a threshold after Gaussian smoothing, which resulted in a binary mask leaving the nuclei blank.”
BackgroundMethodRole for Histone Deacetylase 1 in Human Tumor Cell Proliferation
Senese, S., Zaragoza, K., Minardi, S., Muradore, I., Ronzoni, S., Passafaro, A., Bernard, L., Draetta, G. F., Alcalay, M., Seiser, C., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00494-07 · Cited by 254
“They also induce cell cycle arrest in either G1 or G2/M and apoptosis, killing tumor cells (4, 29, 48).”
BackgroundFaraco, G., Pancani, T., Formentini, L., Mascagni, P., Fossati, G., Leoni, F., Moroni, F., & Chiarugi, A. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.027912 · Cited by 255
“Given the role of histone acetylation in transcriptional activation, as well as the significance of altered gene expression in disease pathogenesis, a great deal of effort has been directed to the development of chemical inhibitors of HDACs (Johnstone, 2002; Dokmanovic and Marks, 2005).”
BackgroundHistone deacetylase inhibitors: from target to clinical trials
Kelly, W. K., O’Connor, O. A., & Marks, P. A. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.12.1695 · Cited by 253
Altered sirtuin expression is associated with node-positive breast cancer
Ashraf, N., Zino, S., MacIntyre, A., Kingsmore, D., Payne, A. P., George, W. D., & Shiels, P. G. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603384 · Cited by 248
“Specifically, genes involved in NADþ -dependent protein deacetylation may have a role to play in cancer pathogenesis (Marks et al, 2001; Johnstone, 2002; Neumeister et al, 2002).”
BackgroundHistone deacetylase inhibitors: Understanding a new wave of anticancer agents
Villar‐Garea, A., & Esteller, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20372 · Cited by 247
“(b) Examples of chemicals included in the different HDAC inhibitor groups (see text): TSA (1) and SAHA (2) are hydroxamic acids; butanoic acid (3), valproic acid (4) and 4-phenylbutanoic acid (5) are carboxylic acids; MS-275 (6) and N-acetyldinaline (7) are benzamides; and depeudecin (8) and trapoxin A (9) are epoxide…”
Dai, Y., Rahmani, M., Dent, P., & Grant, S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5429-5444.2005 · Cited by 245
“, those associated with AML-1/ETO) which block leukemic cell maturation (2) has prompted the development of pharmacological HDAC inhibitors (32).”
BackgroundShah, M. H., Binkley, P., Chan, K., Xiao, J., Arbogast, D., Collamore, M., Farra, Y., Young, D., & Grever, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2689 · Cited by 241
Momparler, R. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206774 · Cited by 242
Modulation of radiation response by histone deacetylase inhibition
Chinnaiyan, P., Vallabhaneni, G., Armstrong, E., Huang, S.-M., & Harari, P. M. (2005) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.12.088 · Cited by 243
Crosstalk between chromatin state and DNA damage response in cellular senescence and cancer.
Sulli, G., Di Micco, R., & di Fagagna, F. D. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3344 · Cited by 238
Taxonomy, Fermentation, Isolation and Biological Activities.
MORI, H., URANO, Y., ABE, F., FURUKAWA, S., FURUKAWA, S., TSURUMI, Y., SAKAMOTO, K., HASHIMOTO, M., TAKASE, S., HINO, M., et al. (2003) · The Journal of Antibiotics · doi:10.7164/antibiotics.56.72 · Cited by 236
Cell Cycle and Checkpoint Regulation of Histone H3 K56 Acetylation by Hst3 and Hst4
Maas, N. L., Miller, K. M., DeFazio, L. G., & Toczyski, D. P. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.06.006 · Cited by 239
“The finding that Sir2-related HDACs are checkpoint targets may also be important pharmacologically, given that previously characterized HDAC inhibitors have proven useful as chemotherapeutics (Johnstone, 2002).”
BackgroundInhibition of HDAC9 Increases T Regulatory Cell Function and Prevents Colitis in Mice
de Zoeten, E. F., Wang, L., Sai, H., Dillmann, W. H., & Hancock, W. W. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.10.037 · Cited by 239
Understanding the role of tissue degrading enzymes and their inhibitors in development and disease
Cawston, T. E., & Wilson, A. J. (2006) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2006.06.007 · Cited by 235
Histone deacetylase inhibitors: Multifunctional anticancer agents
Liu, T., Kuljaca, S., Tee, A., & Marshall, G. M. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2005.12.006 · Cited by 230
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
Garcia-Manero, G., Assouline, S., Cortes, J., Estrov, Z., Kantarjian, H., Yang, H., Newsome, W. M., Miller, W. H., Rousseau, C., Kalita, A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-115873 · Cited by 233
Benzotriazole: An overview on its versatile biological behavior
Briguglio, I., Piras, S., Corona, P., Gavini, E., Nieddu, M., Boatto, G., & Carta, A. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.089 · Cited by 229
“inhibitors can exert in vivo an antitumor effect [214].”
BackgroundShankar, S., & Srivastava, R. (2007) · International Journal of Oncology · doi:10.3892/ijo.30.4.905 · Cited by 235
Arts, J., King, P., Marin, A., Floren, W., Belin, A., Janssen, L., Pilatte, I., Roux, B., Decrane, L., Gilissen, R., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0547 · Cited by 224
Rational Development of Histone Deacetylase Inhibitors as Anticancer Agents: A Review
Acharya, M. R., Sparreboom, A., Venitz, J., & Figg, W. D. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.014167 · Cited by 235
“It remains a challenge to develop specific inhibitors of class I HDACs that are primarily located within the nucleus and class II HDACs that are known to shuttle between nucleus and cytoplasm (Kao et al., 2001; Johnstone, 2002).”
BackgroundInfluentialNovel mechanisms of apoptosis induced by histone deacetylase inhibitors.
Peart, M. J., Tainton, K. M., Ruefli, A. A., Dear, A. E., Sedelies, K. A., O’Reilly, L. A., Waterhouse, N. J., Trapani, J. A., & Johnstone, R. W. (2003) · PubMed · Cited by 259
Self-citationQian, D. Z., Wang, X., Kachhap, S. K., Kato, Y., Wei, Y., Zhang, L., Atadja, P., & Pili, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0540 · Cited by 229
Simonini, M. V., Camargo, L. M., Dong, E., Maloku, E., Veldic, M., Costa, E., & Guidotti, A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510341103 · Cited by 229
HDACs and HDAC inhibitors in colon cancer
Mariadason, J. M. (2008) · Epigenetics · doi:10.4161/epi.3.1.5736 · Cited by 222
Monofunctional and Higher-Valent Platinum Anticancer Agents
Johnstone, T. C., Wilson, J. J., & Lippard, S. J. (2013) · Inorganic Chemistry · doi:10.1021/ic400538c · Cited by 223
Bui, T. P. N., Mannerås-Holm, L., Puschmann, R., Wu, H., Troise, A. D., Nijsse, B., Boeren, S., Bäckhed, F., Fiedler, D., & deVos, W. M. (2021) · Nature Communications · doi:10.1038/s41467-021-25081-w · Cited by 220
HDAC3: taking the SMRT-N-CoRrect road to repression
Karagianni, P., & Wong, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210612 · Cited by 222
“…target In the 30-year period following the discovery of chemical inhibitors of HDACs (Riggs et al., 1977; Vidali et al., 1978), such pharmacological compounds have transited from the laboratory bench to the treatment of cancer patients (reviewed by Johnstone, 2002; Karagiannis and El-Osta, 2007).”
Timchenko, N. A. (2009) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.01.005 · Cited by 219
Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA
Glaser, K. B., Li, J., Staver, M. J., Wei, R.-Q., Albert, D. H., & Davidsen, S. K. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.09.043 · Cited by 218
Rational Combinations Using HDAC Inhibitors
Bots, M., & Johnstone, R. W. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2786 · Cited by 217
Self-citationAbbastabar, M., Kheyrollah, M., Azizian, K., Bagherlou, N., Tehrani, S. S., Maniati, M., & Karimian, A. (2018) · DNA Repair · doi:10.1016/j.dnarep.2018.07.008 · Cited by 212
Metadata
- Authors
- Johnstone, R. W.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- Corresponding author
- Johnstone, Ricky W.
- ORCID
- Johnstone, Ricky W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-04
- Volume
- 1
- Issue
- 4
- Pages
- 287-299
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1971621147
- Cited by
- 1,515
- References
- 121
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 23 · 2023: 46 · 2022: 35 · 2021: 59 · 2020: 50 · 2019: 55 · 2018: 38 · 2017: 65 · 2016: 50 · 2015: 64 · 2014: 54 · 2013: 81 · 2012: 94
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Health and Medical Research Council
- National Medical Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase inhibitors, histone acetyltransferase, chromatin remodeling, gene expression regulation, aberrant transcription, tumor cell growth inhibition, cancer therapy
- MeSH terms
- Acetylation, Animals, Antineoplastic Agents, Cell Differentiation, Chromatin, Clinical Trials as Topic, Enzyme Inhibitors, Histones, Humans, Neoplasms, Gene Expression Regulation, Neoplastic, Apoptosis, DNA Methylation, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.